Clinical trial
An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348(3) With Coadministration of CKD-828, D097 and D337 in Healthy Adult Volunteers
NCT05192356 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348(3) With Coadministration of CKD-828, D097 and D337 in Healthy Adult Volunteers
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 23, 2022
- Completion date
- June 8, 2022
- Enrollment
- 63 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hypertension and dyslipidemia